XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release

Deep News08-26 10:50

XUANZHUBIO-B (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has announced that its board meeting will be held on Wednesday, 26 August 2026, to consider and approve the group's interim results for the six months ended 30 June 2026, as well as to deliberate on any proposed interim dividend.

The recent surge comes on the back of the company's announcement that its next-generation proton pump inhibitor (PPI), Anerazolan Sodium Enteric-Coated Tablets, has received acceptance of its New Drug Application (NDA) from the NMPA for the treatment of adult reflux esophagitis (RE). This NDA is based on results from a domestic Phase III trial that employed a randomized, double-blind design comparing the drug against rabeprazole. Notably, RE marks the second indication for which the company has filed an NDA, following duodenal ulcers.

In a research note, China Post Securities highlighted that Anerazolan exhibits clinical advantages over earlier-generation PPIs, alongside price and safety benefits when compared to PCAB-class drugs. With the product already reaching nearly 3,000 medical institutions, the brokerage believes it holds substantial commercial potential going forward.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169961354?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169961354","market":"sh","top_or_hot":-1,"title":"XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release","media":"Deep News","content":"<p><b>XUANZHUBIO-B</b> (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has announced that its board meeting will be held on Wednesday, 26 August 2026, to consider and approve the group's interim results for the six months ended 30 June 2026, as well as to deliberate on any proposed interim dividend.<br><br>The recent surge comes on the back of the company's announcement that its next-generation proton pump inhibitor (PPI), Anerazolan Sodium Enteric-Coated Tablets, has received acceptance of its New Drug Application (NDA) from the NMPA for the treatment of adult reflux esophagitis (RE). This NDA is based on results from a domestic Phase III trial that employed a randomized, double-blind design comparing the drug against rabeprazole. Notably, RE marks the second indication for which the company has filed an NDA, following duodenal ulcers.<br><br>In a research note, China Post Securities highlighted that Anerazolan exhibits clinical advantages over earlier-generation PPIs, alongside price and safety benefits when compared to PCAB-class drugs. With the product already reaching nearly 3,000 medical institutions, the brokerage believes it holds substantial commercial potential going forward.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-26 10:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>XUANZHUBIO-B</b> (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has announced that its board meeting will be held on Wednesday, 26 August 2026, to consider and approve the group's interim results for the six months ended 30 June 2026, as well as to deliberate on any proposed interim dividend.<br><br>The recent surge comes on the back of the company's announcement that its next-generation proton pump inhibitor (PPI), Anerazolan Sodium Enteric-Coated Tablets, has received acceptance of its New Drug Application (NDA) from the NMPA for the treatment of adult reflux esophagitis (RE). This NDA is based on results from a domestic Phase III trial that employed a randomized, double-blind design comparing the drug against rabeprazole. Notably, RE marks the second indication for which the company has filed an NDA, following duodenal ulcers.<br><br>In a research note, China Post Securities highlighted that Anerazolan exhibits clinical advantages over earlier-generation PPIs, alongside price and safety benefits when compared to PCAB-class drugs. With the product already reaching nearly 3,000 medical institutions, the brokerage believes it holds substantial commercial potential going forward.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1169961354","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169961354","pubTimestamp":1787712647,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"XUANZHUBIO-B (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02575":"轩竹生物-B"},"translate_title":"中期业绩发布前，玄竹生物-B盘中飙升超过8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XUANZHUBIO-B (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has announced that its board meeting will be held on Wednesday, 26 August 2026, to consider and approve the group's interim results for the six months ended 30 June 2026, as well as to deliberate on any proposed interim dividend.The recent surge comes on the back of the company's announcement that its next-generation proton pump inhibitor (PPI), Anerazolan Sodium Enteric-Coated Tablets, has received acceptance of its New Drug Application (NDA) from the NMPA for the treatment of adult reflux esophagitis (RE). This NDA is based on results from a domestic Phase III trial that employed a randomized, double-blind design comparing the drug against rabeprazole. Notably, RE marks the second indication for which the company has filed an NDA, following duodenal ulcers.In a research note, China Post Securities highlighted that Anerazolan exhibits clinical advantages over earlier-generation PPIs, alongside price and safety benefits when compared to PCAB-class drugs. With the product already reaching nearly 3,000 medical institutions, the brokerage believes it holds substantial commercial potential going forward.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169961354","isCrawlerRequest":true}